Can CVS Health's 2028 Split Unlock Value Despite Execution Risks?
CVS Health CVS plans to separate into two publicly traded companies, a move intended to sharpen strategic focus after years of operating an integrated health care model. The transaction is expected to be completed in the first half of 2028.
The case for separation rests on faster decisions, tailored capital allocation and greater operating flexibility. The counterweight is a lengthy implementation period that could bring restructuring costs, dis-synergies and management distraction.
CVS Split Would Create Two Focused Health Businesses
CVS Health would retain Aetna, Caremark, specialty pharmacy, Oak Street Health and Signify Health. The new CVS Pharmacy would house retail pharmacies, mail order, MinuteClinic and Health100, separating community pharmacy from the insurance, pharmacy benefit management and care-delivery platform.
Image Source: Zacks Investment Research
The move contrasts with other large health care models. The Cigna Group CI combines its insurance operations with Evernorth Health Services, which includes Express Scripts, while UnitedHealth Group Incorporated UNH operates UnitedHealthcare alongside Optum’s care, pharmacy and technology businesses.
CVS Could Gain Sharper Capital Allocation After the Split
Management expects dedicated leadership teams to make decisions around the priorities of each business rather than an enterprise-wide capital framework. Greater independence could also improve operating flexibility and make partnerships easier to pursue.
Both companies are expected to maintain solid investment-grade balance sheets and strong free cash flow. That would give each business room to pursue disciplined capital allocation aligned with its own growth opportunities while preserving financial flexibility.
Health100 Gives CVS Pharmacy a Digital Growth Platform
Health100 will remain with CVS Pharmacy. The platform includes Haio, an AI-powered health assistant, and is designed to simplify health care navigation, cost transparency and consumer engagement.
Both companies are expected to continue developing Health100 after the separation. Management believes the structure can accelerate adoption and development, making digital connectivity an important part of CVS Pharmacy’s longer-term strategy rather than simply a retail add-on.
CVS Separation Carries Cost and Dis-Synergy Risks
The separation will require CVS to establish independent operating structures and finalize capital arrangements. Those steps could increase complexity and generate restructuring expenses, business disruption and dis-synergy costs before the strategic benefits become visible.
The timing also overlaps with unfinished operating work. Aetna remains in a multi-year margin recovery, while Caremark faces a 340B earnings reset, a less favorable selling season and health plan client membership attrition entering 2027.
CVS Faces a Long Runway to the 2028 Completion
CVS expects the transaction to close in the first half of 2028, subject to final board approval, effectiveness of a Form 10 filing and customary tax confirmation. Shareholders are expected to own shares in both companies after the separation.
That timetable leaves a substantial period in which business conditions, regulation and competitive pressures can change. Investors therefore have to weigh the strategic logic against execution risk well before the two-company structure is fully established.
CVS Signals Frame the Split With Cautious Optimism
The separation could give both businesses clearer operating mandates and more tailored financial strategies, but the benefits will depend on disciplined execution through 2028. Costs, commercial arrangements between the companies and ongoing turnarounds remain important milestones to monitor.
CVS currently carries a Zacks Rank #3 (Hold), along with a VGM Score of A. Its Value Score of A and Growth Score of A are complemented by a Momentum Score of B, creating a constructive quantitative backdrop while the separation process remains subject to execution risk.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpCVS Health Corporation (CVS) : Free Stock Analysis Report
UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report
Cigna Group (CI) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
